Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-16
2009-02-17
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07491745
ABSTRACT:
The present invention relates to novel Pyrrole-Type compounds, compositions comprising Pyrrole-Type compounds, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a composition comprising a Pyrrole-Type compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell. The present invention also relates to novel Pyrrole-Type compounds, compositions, and methods useful for treating or preventing a viral infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the replication and/or infectivity of a virus.
REFERENCES:
patent: 2673855 (1954-03-01), Nager
patent: 4266028 (1981-05-01), Nakamura et al.
patent: 5691334 (1997-11-01), Doria et al.
patent: 5847127 (1998-12-01), D'Alessio et al.
patent: 6369096 (2002-04-01), D'Alessio et al.
patent: 6407244 (2002-06-01), Murthy et al.
patent: 6602879 (2003-08-01), Murthy et al.
patent: 6638968 (2003-10-01), Kim et al.
patent: 2155096 (1995-06-01), None
patent: 55162768 (1980-12-01), None
patent: 61-34403 (1986-08-01), None
patent: 61280429 (1986-12-01), None
patent: 2-250828 (1990-10-01), None
patent: 5-86374 (1993-12-01), None
patent: 09030967 (1997-02-01), None
patent: 10-120562 (1998-05-01), None
patent: 10-120563 (1998-05-01), None
patent: 11-209283 (1999-08-01), None
patent: WO98/11894 (1998-03-01), None
patent: WO 98/40380 (1998-09-01), None
patent: WO 99/15690 (1999-04-01), None
patent: WO 99/29309 (1999-06-01), None
patent: WO 99/40069 (1999-08-01), None
Gottlieb et al., CID; 37:838-840 (2003).
Galletti et al., Nephrol. Dial. Transplant; 20:1551-8 (2005).
Crawford et al., J. Med. Chem.; 39:2690-95 (1996).
Molecular Biology of The Cell, 1989, Edited by Alberts et al., Garland Publishing, Inc.: New York, pp. 727-761.
Molecular Biology of The Cell, 1989, Edited by Alberts et al., Garland Publishing, Inc.: New York, pp. 1203-1216.
Botti et al., 1998,Int'l. J. Biol Mark. 13:51-69.
Birkeland et al., 2000,Lancet355:1886 and Penn, 2000,Adv. Ren. Replace. Ther. 7:147.
Penn, 2000,Adv. Ren. Replace. Ther. 7:147-154.
Swinnen et al., 2000,Semin. Oncol. 27:402-408.
Appelbaum, 1992,Semin. Oncol. Nurs. 8:51-62.
Cortesina et al., 1993,Head Neck. 15:266-270.
Appelbaum, 1992, “The role of the immune system in the pathogenesis of cancer”, Semin. Oncol. Nurs. 8(1):51-62.
Azuma et al., 2000, “Induction of apoptosis of activated murine splenic T cells by cycloprodigiosin hydrochloride, a novel immunosuppressant”, Immunopharmacology 46(1):29-37.
http://www.dtp.nci.nih.gov/main.html Developmental Therapeutics Program, National Cancer Institute, National Institutes of Health, Apr. 1999.
Balitskii and Struk, 1968, “Activation of Protective Reactions of the Organism in Malignant Growths”, Zh. Eksp. Klin. Med. (USSR) 8:3-8.
Barbagallo et al., 1979, “Cytological Activity of Prodigiosin by Allium cepa L. Test”, Riv. Biol. Norm. Patol. 5:25-31 (in Italian w/ Eng. summary).
Botti et al., 1998, “Immunosupressive factors: role in cancer development and progession”, Int'l. J. Biol. Mark. 13(2):51-69.
Birkeland et al., 2000, “Cancer risk in patients on dialysis and after renal transplantation”, Lancet 355(9218):1886-7.
Cortesina et al., 1993, “Immunomodulation therapy for squamous cell carcinoma of the head and neck”, Head Neck. 15(3):266-70.
Boger and Patel, 1988, “Total Synthesis of Prodigiosin, Prodigiosene, and Desmethoxyprodigiosin: Diels-Alder Reactions of Heterocyclic Azadienes and Development of an Effective Palladium(II)-Promoted 2,2′-Bipyrrole Coupling Procedure”, J. Org. Chem. 53:1405-1415.
Boger and Patel, 1987, “Total Synthesis of Prodigiosin”, Tetrahedron Lett. 28:2499-2502.
D'Alessio and Rossi, 1996, “Short Synthesis of Undecylprodigiosine. A New Route to 2,2′-Bipyrrolyl-Pyrromethene Systems”, Synlett 6:513-514.
Fürstner et al., 1998, “Platinum- and Acid-Catalyzed Enyne Metathesis Reactions: Mechanistic Studies and Applications to the Syntheses of Streptorubin B and Metacycloprodigiosin”, J. Am. Chem. Soc. 120:8305-8314.
Gerber and Gauthier, 1979, “New Prodigiosin-Like Pigment from Alteromonas rubra”, Appl. Environ. Microbiol. 37:1176-1179.
Gerber et al., 1978, “Biosynthesis of Prodiginines.13C Resonance Assignments and Enrichment Patterns in Nonyl-Cyclononyl-, Methylcycodecyl-, and Butylcycloheptylprodiginine Produced by Actinomycete Cultures Supplemented with13C-Labeled Acetate and15N-Labeled Nitrate”, Can. J. Chem. 56:1155-1163.
Gerber and Lechevalier, 1976, “Prodiginine (Prodigiosin-Like) Pigments from Streptomyces and Other Aerobic Actinomycetes”, Can. J. Microbiol. 22:658-667.
Gerber and Stahly, 1975, “Prodiginine (Prodigiosin-Like) Pigments fromStreptoverticillium rubrireticuli, an Organism That Causes Pink Staining of Polyvinyl Chloride”, Appl. Microbiol. 30:807-810.
Gerber, 1975, “Prodigiosin-Like Pigments”, CRC Crit. Rev. Microbiol. 3:469-485.
Gerber, 1975, “A New Prodiginine (Prodigiosin-Like) Pigment from Streptomyces. Antimalarial Activity of Several Prodiginines”, J. Antibiotics 28:194-199.
Gerber, 1973, “Minor Prodiginine Pigments fromActinomadura maduraeandActinomadura pelletieri”, J. Heterocycl. Chem. 10:925-929.
Goping et al., 1998, “Regulated Targeting of BAX to Mitochondria”, J. Cell Biol. 143:207-215.
Guseva and Balshin, 1992, “Comparative Efficacy of Prodigiosan and Proper-Myl Action on Neutrophil Phagocytosis in Acute Myeloblastic Leukemia”, Antibiot. Khimioter. 37:44-46 (in Russian w/Eng. abstr.).
Guseva and Tishenko, 1989, “The Effect of Prodigiosan on Antibody-Dependent Cytotoxicity of Neutrophils in Chronic Myeloid Leukemia”, Vopr. Onkol. 35:30-34 (in Russian w/Eng. abstr.).
Hojo et al., 1999, “Cyclosporine Induces Cancer Progression by a Cell-Autonomous Mechanism”, Nature 397:530-534.
Hong et al., 1999, “Cloning and Functional Analysis of Infectious Pancreatic Necrosis Virus VP5: A Novel Bcl-2 Family with Regulation of Viral Expression and Anti-Cell Death Activity”, Cold Spring Harbor Symposium on Programmed Cell Death, Sep. 29-Oct. 3, 1999, p. 93.
Korsmeyer, 1992, “Bcl-2: A Repressor of Lymphocyte Death”, Immunol. Today 13:285-288.
Laatsch et al., 1991, “Butyl-meta-Cycloheptylprodiginine—a Revision of the Structure of the Former Ortho-Isomer”, J. Antibiot. 44:187-191.
Laatsch and Thomson, 1983, “A Revised Structure for Cycloprodigiosin”, Tetrahedron Lett. 24:2701-2704.
Magae et al., 1996, “Effect of Metacycloprodigiosin, an Inhibitor of Killer T Cells, on Murine Skin and Heart Transplants”, J. Antibiot. 49:86-90.
Marshall et al., 1999, “Epstein-Barr Virus Encodes a Novel Homolog of the bcl-2 Oncogene That Inhibits Apoptosis and Associates with Bax and Bak”, J. Virol. 73:5181-5185.
Matsunaga et al., 1986, “Bioactive Marine Metabolites. VIII. Isolation of an Antimicrobial Blue Pigment from the BryozoanBugula dentata”, Experientia 42:84.
http://dbs.p.kanazawa-u.ac.jp/˜seika/home-e.html Faculty of Pharmaceutical Science at the University of Kanazawa.
The Merck Index (12th ed. 1996) entry 7948, p. 1334.
Mitsuya et al., 1991, “Targeted Therapy of Human Immunodeficiency Virus-Related Disease”, FASEB J. 5:2369-2381.
Molecular Biology of the Cell (2nd ed. 1989) edited by Alberts et al., Garland Publishing, Inc.:New York, pp. 727-761 and 1203-1215.
Montaner et al., 2000, “Prodigiosin from the supernatant ofSerratia marcescensinduces apoptosis in haematopoietic cancer cell lines”, Br. J. Pharmacol. 131(3):585-93.
Mortellaro et al., 1999, “New Immunosuppressive Drug PNU156804 Blocks IL-2 Dependent Proliferation and NF-κB and AP-1 Activation”, J. Immunol. 162:7102-7109.
Myasoedov et al.,
Attardo Giorgio
Johnson Roy A.
Gemin X Pharmaceuticals Canada inc.
Sackey Ebenezer
Wilmer Cutler Pickering Hale & Dorr LLP.
Wilson James O
LandOfFree
Pyrrole-Type compounds, compositions and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrole-Type compounds, compositions and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrole-Type compounds, compositions and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4098410